| | | | | | Préparation | Taille des prés. | PEF | PP | QP | CQ | Composition | Titulaire de l'aut. | Cat. | | | | |
|---|
|
| L | | IPro | IPat | CM | Rivastigmin Patch Sandoz 5 | 30 | 39.51 | 59.40 | 10% | | Timbre transdermique: Rivastigminum 9 mg | Sandoz
Pharmaceuticals AG | B / LS / SG | FB | | G |  |
| L | | IPro | | CM | Rivastigmin Patch Sandoz 10 | 30 | 39.51 | 59.40 | 10% | | Timbre transdermique: Rivastigminum 18 mg | Sandoz
Pharmaceuticals AG | B / LS / SG | FB | | G | |
| L | | IPro | | CM | Rivastigmin Patch Sandoz 10 | 60 | 79.02 | 102.35 | 10% | | Timbre transdermique: Rivastigminum 18 mg | Sandoz
Pharmaceuticals AG | B / LS / SG | FB | | G | |
| L | | IPro | | CM | Rivastigmin Patch Sandoz 15 | 30 | 39.51 | 59.40 | 10% | | Timbre transdermique: Rivastigminum 27 mg | Sandoz
Pharmaceuticals AG | B / LS / SG | FB | | G | |
| L | | IPro | | CM | Rivastigmin Patch Sandoz 15 | 60 | 79.02 | 102.35 | 10% | | Timbre transdermique: Rivastigminum 27 mg | Sandoz
Pharmaceuticals AG | B / LS / SG | FB | | G | |
| | | | | | Rivasur zweimal
wöchentlich 4,6 mg/24
Stunden | 2 | DDP | DDP | N.O. | | Timbre transdermique: (Transdermales Pflaster): Rivastigminum 25.92 mg | Luye Pharma
Switzerland AG | B | FB | | G | |
| | | | | | Rivasur zweimal
wöchentlich 4,6 mg/24
Stunden | 8 | DDP | DDP | N.O. | | Timbre transdermique: (Transdermales Pflaster): Rivastigminum 25.92 mg | Luye Pharma
Switzerland AG | B | FB | | G | |
| | | | | | Rivasur zweimal
wöchentlich 4,6 mg/24
Stunden | 16 | DDP | DDP | N.O. | | Timbre transdermique: (Transdermales Pflaster): Rivastigminum 25.92 mg | Luye Pharma
Switzerland AG | B | FB | | G | |
| | | | | | Rivasur zweimal
wöchentlich 4,6 mg/24
Stunden | 24 | DDP | DDP | N.O. | | Timbre transdermique: (Transdermales Pflaster): Rivastigminum 25.92 mg | Luye Pharma
Switzerland AG | B | FB | | G | |
| | | | | | Rivasur zweimal
wöchentlich 9,5 mg/24
Stunden | 2 | DDP | DDP | N.O. | | Timbre transdermique: (Transdermales Pflaster): Rivastigminum 51.84 mg | Luye Pharma
Switzerland AG | B | FB | | G | |
| | | | | | Rivasur zweimal
wöchentlich 9,5 mg/24
Stunden | 8 | DDP | DDP | N.O. | | Timbre transdermique: (Transdermales Pflaster): Rivastigminum 51.84 mg | Luye Pharma
Switzerland AG | B | FB | | G | |
| | | | | | Rivasur zweimal
wöchentlich 9,5 mg/24
Stunden | 16 | DDP | DDP | N.O. | | Timbre transdermique: (Transdermales Pflaster): Rivastigminum 51.84 mg | Luye Pharma
Switzerland AG | B | FB | | G | |
| | | | | | Rivasur zweimal
wöchentlich 9,5 mg/24
Stunden | 24 | DDP | DDP | N.O. | | Timbre transdermique: (Transdermales Pflaster): Rivastigminum 51.84 mg | Luye Pharma
Switzerland AG | B | FB | | G | |
| L | | IPro | IPat | | Exelon Patch 5 | 30 pansement(s) | 53.24 | 73.45 | 40% | | Timbre transdermique: Rivastigminum 9 mg | Novartis Pharma
Schweiz AG | B / LS / SO | FB | | G | |
| L | | IPro | IPat | | Exelon Patch 10 | 30 pansement(s) | 53.24 | 73.45 | 40% | | Timbre transdermique: Rivastigminum 18 mg | Novartis Pharma
Schweiz AG | B / LS / SO | FB | | G | |
| L | | IPro | IPat | | Exelon Patch 10 | 60 pansement(s) | 106.48 | 130.55 | 40% | | Timbre transdermique: Rivastigminum 18 mg | Novartis Pharma
Schweiz AG | B / LS / SO | FB | | G | |
| L | | IPro | IPat | | Exelon Patch 15 | 30 pansement(s) | 53.24 | 73.45 | 40% | | Timbre transdermique: Rivastigminum 27 mg | Novartis Pharma
Schweiz AG | B / LS / SO | FB | | G | |
| L | | IPro | IPat | | Exelon Patch 15 | 60 pansement(s) | 106.48 | 130.55 | 40% | | Timbre transdermique: Rivastigminum 27 mg | Novartis Pharma
Schweiz AG | B / LS / SO | FB | | G | |
| L | | IPro | IPat | | Rivastigmin Zentiva Patch 4.6
mg/24 h | 30 | 39.51 | 59.40 | 10% | | Timbre transdermique: Rivastigminum 6.9 mg | Helvepharm AG | B / LS / SG | FB | | G | |
| L | | IPro | IPat | | Rivastigmin Zentiva Patch 9.5
mg/24 h | 30 | 39.51 | 59.40 | 10% | | Timbre transdermique: Rivastigminum 13.8 mg | Helvepharm AG | B / LS / SG | FB | | G | |
| L | | IPro | IPat | | Rivastigmin Zentiva Patch 9.5
mg/24 h | 2 x 30 | 79.02 | 102.35 | 10% | | Timbre transdermique: Rivastigminum 13.8 mg | Helvepharm AG | B / LS / SG | FB | | G | |
| L | | IPro | | | Rivastigmin Zentiva Patch
13.3 mg/24 h | 30 | 39.51 | 59.40 | 10% | | Timbre transdermique: Rivastigminum 19.2 mg | Helvepharm AG | B / LS / SG | FB | | G | |
| L | | IPro | | | Rivastigmin Zentiva Patch
13.3 mg/24 h | 2 x 30 | 79.02 | 102.35 | 10% | | Timbre transdermique: Rivastigminum 19.2 mg | Helvepharm AG | B / LS / SG | FB | | G | |
| L | | IPro | IPat | | Rivastigmin-Mepha Patch 4.6
mg/24 h | 30 | 39.51 | 59.40 | 10% | | Transdermale Pflaster: Rivastigminum 6.4 mg | Mepha Pharma AG | B / LS / SG | FB | | G | |
| L | | IPro | | | Rivastigmin-Mepha Patch 9.5
mg/24 h | 30 | 39.51 | 59.40 | 10% | | Transdermale Pflaster: Rivastigminum 12.8 mg | Mepha Pharma AG | B / LS / SG | FB | | G | |
| L | | IPro | | | Rivastigmin-Mepha Patch 9.5
mg/24 h | 2 x 30 | 79.02 | 102.35 | 10% | | Transdermale Pflaster: Rivastigminum 12.8 mg | Mepha Pharma AG | B / LS / SG | FB | | G | |
| L | | IPro | | | Rivastigmin-Mepha Patch
13.3 mg/24 h | 30 | 39.51 | 59.40 | 10% | | Transdermale Pflaster: Rivastigminum 19.2 mg | Mepha Pharma AG | B / LS / SG | FB | | G | |
| L | | IPro | | | Rivastigmin-Mepha Patch
13.3 mg/24 h | 2 x 30 | 79.02 | 102.35 | 10% | | Transdermale Pflaster: Rivastigminum 19.2 mg | Mepha Pharma AG | B / LS / SG | FB | | G | |
| L | | IPro | IPat | | Exelon 1,5 mg - C | 28 Gélule(s) | 23.73 | 42.20 | 10% | | Capsules: Rivastigminum 1.5 mg | Novartis Pharma
Schweiz AG | B / LS | FB | | G | |
| L | | IPro | IPat | | Exelon 1,5 mg - C | 56 Gélule(s) | 42.53 | 62.65 | 10% | | Capsules: Rivastigminum 1.5 mg | Novartis Pharma
Schweiz AG | B / LS | FB | | G | |
| L | | IPro | IPat | | Exelon 1,5 mg - C | 112 Gélule(s) | 93.27 | 117.85 | 10% | | Capsules: Rivastigminum 1.5 mg | Novartis Pharma
Schweiz AG | B / LS | FB | | G | |
| L | | IPro | IPat | | Exelon 3 mg - C | 28 Gélule(s) | 23.73 | 42.20 | 10% | | Capsules: Rivastigminum 3 mg | Novartis Pharma
Schweiz AG | B / LS | FB | | G | |
| L | | IPro | IPat | | Exelon 3 mg - C | 56 Gélule(s) | 42.53 | 62.65 | 10% | | Capsules: Rivastigminum 3 mg | Novartis Pharma
Schweiz AG | B / LS | FB | | G | |
| L | | IPro | IPat | | Exelon 3 mg - C | 112 Gélule(s) | 93.27 | 117.85 | 10% | | Capsules: Rivastigminum 3 mg | Novartis Pharma
Schweiz AG | B / LS | FB | | G | |
| L | | IPro | IPat | | Exelon 4,5 mg - C | 28 Gélule(s) | 23.73 | 42.20 | 10% | | Capsules: Rivastigminum 4.5 mg | Novartis Pharma
Schweiz AG | B / LS | FB | | G | |
| L | | IPro | IPat | | Exelon 4,5 mg - C | 112 Gélule(s) | 93.27 | 117.85 | 10% | | Capsules: Rivastigminum 4.5 mg | Novartis Pharma
Schweiz AG | B / LS | FB | | G | |
| L | | IPro | IPat | | Exelon 6 mg - C | 28 Gélule(s) | 23.73 | 42.20 | 10% | | Capsules: Rivastigminum 6 mg | Novartis Pharma
Schweiz AG | B / LS | FB | | G | |
| L | | IPro | IPat | | Exelon 6 mg - C | 112 Gélule(s) | 93.27 | 117.85 | 10% | | Capsules: Rivastigminum 6 mg | Novartis Pharma
Schweiz AG | B / LS | FB | | G | |
| L | | IPro | IPat | | Exelon 2 mg/ml | 120 ml | 68.98 | 91.45 | 10% | | Solution (orale): Rivastigminum 2 mg/ml | Novartis Pharma
Schweiz AG | B / LS | FB | | G | |
